Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Correction to: Parma consensus statement on metabolic disruptors.

Heindel JJ, Vom Saal FS, Blumberg B, Bovolin P, Calamandrei G, Ceresini G, Cohn BA, Fabbri E, Gioiosa L, Kassotis C, Legler J, La Merrill M, Rizzi L, Machtinger R, Mantovani A, Mendez MA, Montanini L, Molteni L, Nagel SC, Parmigiani S, Panzica G, Paterlini S, Pomatto V, Ruzzin J, Sartor G, Schug TT, Street ME, Suvorov A, Volpi R, Zoeller RT, Palanza P.

Environ Health. 2017 Dec 6;16(1):130. doi: 10.1186/s12940-017-0343-0.

2.

Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic.

Mendrick DL, Diehl AM, Topor LS, Dietert RR, Will Y, La Merrill MA, Bouret S, Varma V, Hastings KL, Schug TT, Emeigh Hart SG, Burleson FG.

Toxicol Sci. 2018 Mar 1;162(1):36-42. doi: 10.1093/toxsci/kfx233. Review.

3.

Minireview: Endocrine Disruptors: Past Lessons and Future Directions.

Schug TT, Johnson AF, Birnbaum LS, Colborn T, Guillette LJ Jr, Crews DP, Collins T, Soto AM, Vom Saal FS, McLachlan JA, Sonnenschein C, Heindel JJ.

Mol Endocrinol. 2016 Aug;30(8):833-47. doi: 10.1210/me.2016-1096. Epub 2016 Jul 19. Review.

4.

Endocrine disruptors and obesity.

Heindel JJ, Newbold R, Schug TT.

Nat Rev Endocrinol. 2015 Nov;11(11):653-61. doi: 10.1038/nrendo.2015.163. Epub 2015 Sep 22. Review.

PMID:
26391979
5.

NIEHS/FDA CLARITY-BPA research program update.

Heindel JJ, Newbold RR, Bucher JR, Camacho L, Delclos KB, Lewis SM, Vanlandingham M, Churchwell MI, Twaddle NC, McLellen M, Chidambaram M, Bryant M, Woodling K, Gamboa da Costa G, Ferguson SA, Flaws J, Howard PC, Walker NJ, Zoeller RT, Fostel J, Favaro C, Schug TT.

Reprod Toxicol. 2015 Dec;58:33-44. doi: 10.1016/j.reprotox.2015.07.075. Epub 2015 Jul 29. Review.

6.

Parma consensus statement on metabolic disruptors.

Heindel JJ, Vom Saal FS, Blumberg B, Bovolin P, Calamandrei G, Ceresini G, Cohn BA, Fabbri E, Gioiosa L, Kassotis C, Legler J, La Merrill M, Rizzir L, Machtinger R, Mantovani A, Mendez MA, Montanini L, Molteni L, Nagel SC, Parmigiani S, Panzica G, Paterlini S, Pomatto V, Ruzzin J, Sartor G, Schug TT, Street ME, Suvorov A, Volpi R, Zoeller RT, Palanza P.

Environ Health. 2015 Jun 20;14:54. doi: 10.1186/s12940-015-0042-7. Erratum in: Environ Health. 2017 Dec 6;16(1):130.

7.

Elucidating the links between endocrine disruptors and neurodevelopment.

Schug TT, Blawas AM, Gray K, Heindel JJ, Lawler CP.

Endocrinology. 2015 Jun;156(6):1941-51. doi: 10.1210/en.2014-1734. Epub 2015 Feb 25.

8.

Evolution of DOHaD: the impact of environmental health sciences.

Haugen AC, Schug TT, Collman G, Heindel JJ.

J Dev Orig Health Dis. 2015 Apr;6(2):55-64. doi: 10.1017/S2040174414000580. Epub 2014 Dec 4.

9.

Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.

Juberg DR, Borghoff SJ, Becker RA, Casey W, Hartung T, Holsapple MP, Marty MS, Mihaich EM, Van Der Kraak G, Wade MG, Willett CE, Andersen ME, Borgert CJ, Coady KK, Dourson ML, Fowle JR 3rd, Gray LE, Lamb JC, Ortego LS, Schug TT, Toole CM, Zorrilla LM, Kroner OL, Patterson J, Rinckel LA, Jones BR.

ALTEX. 2014;31(1):63-78. doi: 10.14573/altex.1309171. Epub 2013 Oct 10.

10.

SIRT4 represses peroxisome proliferator-activated receptor α activity to suppress hepatic fat oxidation.

Laurent G, de Boer VC, Finley LW, Sweeney M, Lu H, Schug TT, Cen Y, Jeong SM, Li X, Sauve AA, Haigis MC.

Mol Cell Biol. 2013 Nov;33(22):4552-61. doi: 10.1128/MCB.00087-13. Epub 2013 Sep 16.

11.

Working together: research- and science-based regulation of BPA.

Birnbaum LS, Aungst J, Schug TT, Goodman JL.

Environ Health Perspect. 2013 Jul;121(7):A206-7. doi: 10.1289/ehp.1306963. No abstract available.

12.

The perfect storm for obesity.

Heindel JJ, Schug TT.

Obesity (Silver Spring). 2013 Jun;21(6):1079-80. doi: 10.1002/oby.20222.

13.

A new approach to synergize academic and guideline-compliant research: the CLARITY-BPA research program.

Schug TT, Heindel JJ, Camacho L, Delclos KB, Howard P, Johnson AF, Aungst J, Keefe D, Newbold R, Walker NJ, Thomas Zoeller R, Bucher JR.

Reprod Toxicol. 2013 Sep;40:35-40. doi: 10.1016/j.reprotox.2013.05.010. Epub 2013 Jun 5. Review.

PMID:
23747832
14.

Nano GO Consortium--a team science approach to assess engineered nanomaterials: reliable assays and methods.

Schug TT, Nadadur SS, Johnson AF.

Environ Health Perspect. 2013 Jun;121(6):A176-7. doi: 10.1289/ehp.1306866. No abstract available.

15.

ONE Nano: NIEHS's strategic initiative on the health and safety effects of engineered nanomaterials.

Schug TT, Johnson AF, Balshaw DM, Garantziotis S, Walker NJ, Weis C, Nadadur SS, Birnbaum LS.

Environ Health Perspect. 2013 Apr;121(4):410-4. doi: 10.1289/ehp.1206091. Epub 2013 Feb 12.

16.

Fetal programming and environmental exposures: implications for prenatal care and preterm birth.

Schug TT, Erlebacher A, Leibowitz S, Ma L, Muglia LJ, Rando OJ, Rogers JM, Romero R, vom Saal FS, Wise DL.

Ann N Y Acad Sci. 2012 Dec;1276:37-46. doi: 10.1111/nyas.12003.

17.

Designing Endocrine Disruption Out of the Next Generation of Chemicals.

Schug TT, Abagyan R, Blumberg B, Collins TJ, Crews D, DeFur PL, Dickerson SM, Edwards TM, Gore AC, Guillette LJ, Hayes T, Heindel JJ, Moores A, Patisaul HB, Tal TL, Thayer KA, Vandenberg LN, Warner J, Watson CS, Saal FS, Zoeller RT, O'Brien KP, Myers JP.

Green Chem. 2013 Jan;15(1):181-198.

18.

Consortium-based science: the NIEHS's multipronged, collaborative approach to assessing the health effects of bisphenol A.

Birnbaum LS, Bucher JR, Collman GW, Zeldin DC, Johnson AF, Schug TT, Heindel JJ.

Environ Health Perspect. 2012 Dec;120(12):1640-4. doi: 10.1289/ehp.1205330. Epub 2012 Sep 25.

19.

PPTOX III: environmental stressors in the developmental origins of disease--evidence and mechanisms.

Schug TT, Barouki R, Gluckman PD, Grandjean P, Hanson M, Heindel JJ.

Toxicol Sci. 2013 Feb;131(2):343-50. doi: 10.1093/toxsci/kfs267. Epub 2012 Sep 5.

20.

Endocrine disrupting chemicals and disease susceptibility.

Schug TT, Janesick A, Blumberg B, Heindel JJ.

J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):204-15. doi: 10.1016/j.jsbmb.2011.08.007. Epub 2011 Aug 27. Review.

21.

Targeting transcription through inhibition of TBP.

Schug TT.

Oncotarget. 2011 Jan-Feb;2(1-2):5-7. No abstract available.

22.

Sirtuin 1 in lipid metabolism and obesity.

Schug TT, Li X.

Ann Med. 2011 May;43(3):198-211. doi: 10.3109/07853890.2010.547211. Epub 2011 Feb 24. Review.

23.

Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress.

Schug TT, Xu Q, Gao H, Peres-da-Silva A, Draper DW, Fessler MB, Purushotham A, Li X.

Mol Cell Biol. 2010 Oct;30(19):4712-21. doi: 10.1128/MCB.00657-10. Epub 2010 Jul 20.

24.

mTOR favors senescence over quiescence in p53-arrested cells.

Schug TT.

Aging (Albany NY). 2010 Jun;2(6):327-8. No abstract available.

25.

The skinny on SIRT1 regulation.

Schug TT.

Dis Model Mech. 2010 Sep-Oct;3(9-10):507-8. doi: 10.1242/dmm.005629. Epub 2010 May 18. No abstract available.

26.

Surprising sirtuin crosstalk in the heart.

Schug TT, Li X.

Aging (Albany NY). 2010 Mar 31;2(3):129-32. No abstract available.

27.

DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1.

Guo X, Williams JG, Schug TT, Li X.

J Biol Chem. 2010 Apr 23;285(17):13223-32. doi: 10.1074/jbc.M110.102574. Epub 2010 Feb 18.

28.

Awakening p53 in senescent cells using nutlin-3.

Schug TT.

Aging (Albany NY). 2009 Oct 13;1(10):842-4. No abstract available.

29.

SIRT1 performs a balancing act on the tight-rope toward longevity.

Purushotham A, Schug TT, Li X.

Aging (Albany NY). 2009 Jul 30;1(7):669-73.

30.

PPARdelta-mediated macrophage activation: a matter of fat.

Schug TT, Li X.

Dis Model Mech. 2009 Sep-Oct;2(9-10):421-2. doi: 10.1242/dmm.003913. No abstract available.

31.

Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation.

Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X.

Cell Metab. 2009 Apr;9(4):327-38. doi: 10.1016/j.cmet.2009.02.006.

32.

Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR.

Schug TT, Berry DC, Toshkov IA, Cheng L, Nikitin AY, Noy N.

Proc Natl Acad Sci U S A. 2008 May 27;105(21):7546-51. doi: 10.1073/pnas.0709981105. Epub 2008 May 21.

33.

Supplemental Content

Loading ...
Support Center